Free Trial
→ The only 5 stocks that matter (From TradeSmith) (Ad)tc pixel Free UPC Stock Alerts

Universe Pharmaceuticals (UPC) Competitors

Universe Pharmaceuticals logo
$4.15 -0.03 (-0.72%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$4.21 +0.06 (+1.47%)
As of 10/9/2026 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UPC vs. ICCC, CGTX, FBIO, VRCA, and ALDX

Should you buy Universe Pharmaceuticals stock or one of its competitors? Universe Pharmaceuticals's main competitors and comparable companies include ImmuCell (ICCC), Cognition Therapeutics (CGTX), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), and Aldeyra Therapeutics (ALDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Universe Pharmaceuticals compare to ImmuCell?

Universe Pharmaceuticals (NASDAQ:UPC) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Universe Pharmaceuticals had 3 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 1 mentions for ImmuCell. Universe Pharmaceuticals' average media sentiment score of 0.61 beat ImmuCell's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
ImmuCell Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

ImmuCell has a net margin of 2.57% compared to Universe Pharmaceuticals' net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Universe Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
ImmuCell 2.57%2.69%1.76%

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Universe Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

ImmuCell has higher revenue and earnings than Universe Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.17-$3.67MN/AN/A
ImmuCell$27.64M3.22-$1.04M$0.08122.50

Summary

ImmuCell beats Universe Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Cognition Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Universe Pharmaceuticals had 3 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 1 mentions for Cognition Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.61 beat Cognition Therapeutics' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Cognition Therapeutics Neutral

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Universe Pharmaceuticals' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Cognition Therapeutics N/A -50.17%-40.22%

Universe Pharmaceuticals has higher revenue and earnings than Cognition Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.17-$3.67MN/AN/A
Cognition TherapeuticsN/AN/A-$23.49M-$0.17N/A

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Universe Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Summary

Universe Pharmaceuticals beats Cognition Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Fortress Biotech?

Universe Pharmaceuticals (NASDAQ:UPC) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Universe Pharmaceuticals had 3 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 1 mentions for Fortress Biotech. Universe Pharmaceuticals' average media sentiment score of 0.61 beat Fortress Biotech's score of -0.03 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Fortress Biotech Neutral

Fortress Biotech has higher revenue and earnings than Universe Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.17-$3.67MN/AN/A
Fortress Biotech$63.26M1.12$6.82M$2.640.81

Fortress Biotech has a net margin of 163.32% compared to Universe Pharmaceuticals' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Universe Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Fortress Biotech 163.32%83.47%42.98%

Universe Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 698.12%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Fortress Biotech
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Fortress Biotech beats Universe Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Verrica Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Universe Pharmaceuticals has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 208.19%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Verrica Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Universe Pharmaceuticals' score of 0.61 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Universe Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verrica Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Universe Pharmaceuticals has higher earnings, but lower revenue than Verrica Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.17-$3.67MN/AN/A
Verrica Pharmaceuticals$35.58M1.98-$17.89M-$1.67N/A

Universe Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Universe Pharmaceuticals' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Verrica Pharmaceuticals -102.84%-407.11%-70.17%

Summary

Universe Pharmaceuticals and Verrica Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Aldeyra Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Universe Pharmaceuticals had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.61 beat Aldeyra Therapeutics' score of -0.29 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Aldeyra Therapeutics Neutral

Universe Pharmaceuticals has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.17-$3.67MN/AN/A
Aldeyra TherapeuticsN/AN/A-$33.85M-$0.39N/A

Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 500.24%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aldeyra Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Universe Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Aldeyra Therapeutics N/A -53.14%-34.94%

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Universe Pharmaceuticals beats Aldeyra Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

Export
MetricUniverse PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21M$12.29B$7.16B$13.21B
Dividend YieldN/A2.64%2.53%16.37%
P/E RatioN/A797.58275.3026.16
Price / Sales1.17939.75635.97107.50
Price / CashN/A85.9776.3853.09
Price / Book0.0410.7111.226.33
Net Income-$3.67M$2.84B$3.50B$382.15M
7 Day Performance-7.78%-0.94%-0.89%-1.40%
1 Month Performance6.96%-4.89%-4.42%-3.47%
1 Year Performance-38.15%-4.12%7.03%1.18%

Universe Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPC
Universe Pharmaceuticals
1.0696 of 5 stars		$4.15
-0.7%		N/A-42.5%$21M$17.86MN/A216
ICCC
ImmuCell
1.0413 of 5 stars		$9.88
-0.5%		N/A+45.8%$90.14M$27.64M123.5273
CGTX
Cognition Therapeutics
2.3407 of 5 stars		$0.94
+0.2%		$3.33
+255.2%		-55.0%$89.06MN/AN/A14
FBIO
Fortress Biotech
2.5062 of 5 stars		$2.17
-4.8%		$17.00
+683.4%		-23.9%$76.04M$63.26M0.8278
VRCA
Verrica Pharmaceuticals
3.9541 of 5 stars		$4.60
+5.3%		$12.67
+175.4%		-4.4%$75.07M$35.58MN/A76

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel